[Clinical study of nephrotoxicity following cis-diamminedichloroplatinum (II) (CDDP) combination chemotherapy assessed by 131I-OIH renogram].
The renal function in 26 patients with malignant tumors (19 non-small cell lung cancers, 4 small cell lung cancers, 1 malignant lymphoma, 1 esophageal cancer, 1 malignant thymoma) who were treated with 43 times combination chemotherapy including CDDP was evaluated prospectively, by measuring of creatinine clearance (Ccr), fractional excretion of beta-2-microglobulin (FE beta 2MG), urinary N-acetyl-beta-glucosaminidase (NAG), and 131I-OIH or 123I-OIH renogram. The comparison of renogram and other parameters showed significant change in renogram (23/43, 53.5%), however other parameters such as Ccr, FE beta 2MG, NAG altered in only 10.3-34.9%. After the administration of CDDP, renograms were divided into distinctive 4 patterns as follows: 1) aggravation of obstructive pattern 2) early plateau pattern in excretory phase 3) intermittent pattern in excretory phase 4) prolongation of secretory phase. We consider these patterns suggest some obstructive change of urinary tract microscopically, that is proximal tubules damage due to cellular necrosis and tubular dilatation by CDDP. 131I-OIH or 123I-OIH renogram in delayed phase is useful for detection of renal dysfunction by CDDP administration.
Shirasaka
K
K
Department of Radiology, Kobe University School of Medicine.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007465:Iodohippuric Acid; D007668:Kidney / Q000000981:diagnostic imaging / Q000187:drug effects; D007674:Kidney Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D011866:Radioisotope Renography
D009944:Organoplatinum Compounds; D007465:Iodohippuric Acid; C055423:didimethylsulfoxide dichloroplatinum(II)